Continuous infusion recombinant interleukin-2 (rIL-2) in adoptive cellular therapy of renal carcinoma and other malignancies.
West
W H
WH
Baptist Memorial Hospital, Memphis, TN.
D002292:Carcinoma, Renal Cell / Q000276:immunology / Q000556:secondary / Q000628:therapy*; D003404:Creatinine / Q000097:blood; D004334:Drug Administration Schedule; D006801:Humans; D007022:Hypotension / Q000209:etiology; D007167:Immunotherapy; D007262:Infusions, Intravenous; D007376:Interleukin-2 / Q000008:administration & dosage* / Q000009:adverse effects; D007680:Kidney Neoplasms / Q000276:immunology / Q000628:therapy*; D007963:Leukocytes, Mononuclear / Q000276:immunology*; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D012074:Remission Induction
D007376:Interleukin-2; D003404:Creatinine